Peking University Weiming Biotech Group

Peking University Weiming Biotech Group, also known as Sinobioway, is a prominent Chinese biotechnology conglomerate established in 1992 by Peking University. The group operates as a pioneer in the bio-economy sector, with business interests spanning bio-pharmaceuticals, bio-agriculture, bio-energy, and bio-environmental protection. Its core pharmaceutical portfolio includes marketed recombinant protein drugs such as interferon alpha-2b and human insulin, alongside a robust pipeline in cell therapies and vaccines. Sinobioway is notably recognized for its historical involvement and equity stakes in major entities like Sinovac Biotech and its listed subsidiary, Shandong Weiming Biological Engineering. The company maintains large-scale manufacturing bases in Xiamen and Hefei, focusing on GMP-compliant production of biologics. Despite recent financial restructuring challenges, it remains a key player in China's strategic development of the life sciences industry.